ArticleTranslational lung cancer research2015
CHRNA3 rs1051730 polymorphism and lung cancer susceptibility in Asian population: a meta-analysis.
Article in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 6 citations in OpenAlex.
- Chronic Cerebral Hypoxia and Cognitive Impairment: A Systematic Review and Meta-Analysis Based on Chronic Mountain Sickness, Anemia, Chronic Obstructive Pulmonary Disease, and Obstructive Sleep Apnea.CNS neuroscience & therapeutics · 2026Pooled it
- Analyzing large-scale samples confirms the association between the rs1051730 polymorphism and lung cancer susceptibility.Scientific reports · 2015Pooled it
- CHRNA5 and CHRNA3 polymorphism and lung cancer susceptibility in Palestinian population.BMC research notes · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies have examined the association between the CHRNA3 rs1051730 polymorphism gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent. The PubMed was searched for case-control studies published up to Jan 01, 2015. Data were extracted and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. In this meta-analysis, we assessed four published studies involving comprising 2,890 lung cancer cases and 2,521 controls of the association between CHRNA3 rs1051730 polymorphism and lung cancer risk. For the T allele carriers (C/T + T/T) and the homozygote T/T, the pooled ORs for all studies combined 2,890 cases and 2,521 controls were 1.93 (95% CI =1.48-2.53, P=0.34 for heterogeneity) and 1.63 (95% CI =1.27-1.99, P=0.46 for heterogeneity), when compared with the homozygous wild-type genotype (C/C). There was no observable publication bias for both polymorphisms. These results from the meta-analysis suggest that CHRNA3 rs1051730 polymorphism contributes to risk of lung cancer among Asian population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.